Ramipril research papers are retracted over faked dataBMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h5035 (Published 21 September 2015) Cite this as: BMJ 2015;351:h5035
All rapid responses
While JAMA and Circulation Research de-accept faked papers on antihypertensive medication; and Cheryl Travassa reports in the BMJ that high BP is a leading health risk in India; and the NIH interrupts a study because its claim that BPs should be driven lower with more intensive medication is held to be already well supported; and it is widely reported that heat waves in India this summer lead to the deaths of many of the elderly (many of whom were likely on antihypertensive medication - while all these news items confronted us, the editors of leading medical journals were consistently refusing to send out for review my case report of seasonal (hot weather) hypersensitivity to antihypertensive medication.
Eventually it was published in BMC Research Notes (8, 227; see Figure 1), and the absurd publication saga was described in the Journal of Evaluation in Clinical Practice (see URL below). Although clear from the literature that mine was not an isolated example, I expect the litany of cruel hypotensive incidents following overzealous medication to greatly expand in the years ahead.
Legend: Figure 1 Monthly variation in the average daily losartan dose needed to keep BP in the 130/80 (mmHg) range in an elderly male subject.
Symbols for the 12-year period (2003–2014):
2003, black triangles; 2004, dark yellow triangles;
2005, green circles; 2006, black squares;
2007, blue diamonds; 2008, orange squares;
2009, grey triangles; 2010, red diamonds;
2011, cyan circles; 2012, black circles;
2013, green diamonds; 2014, dark red circles.
2012–2014 data include standard errors (Reproduced under Creative Commons Licence)
Competing interests: No competing interests